Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 immunochromatographic IgM/IgG rapid test in pregnancy: A false friend?

  • Fabre, M.
  • Ruiz-Martinez, S.
  • Monserrat Cantera, M.E.
  • Cortizo Garrido, A.
  • Beunza Fabra, Z.
  • Peran, M.
  • Benito, R.
  • Mateo, P.
  • Paules, C.
  • Oros, D.
Background: An increasing body of evidence has revealed that SARS-CoV-2 infection in pregnant women could increase the risk of adverse maternal and fetal outcomes. Careful monitoring of pregnancies with COVID-19 and measures to prevent neonatal infection are warranted. Therefore, rapid antibody tests have been suggested as an efficient screening tool during pregnancy. Cases: We analysed the clinical performance during pregnancy of a rapid, lateral-flow immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies. We performed a universal screening including 169 patients during their last trimester of pregnancy. We present a series of 14 patients with positive SARS-CoV-2 immunochromatographic assay rapid test result. Immunochromatographic assay results were always confirmed by chemiluminescent microparticle immunoassays for quantitative detection of SARS-CoV-2 IgG and IgM+IgA antibodies as the gold standard. We observed a positive predictive value of 50% and a false positive rate of 50% in pregnant women, involving a significantly lower diagnostic performance than reported in non-pregnant patients. Discussion: Our data suggest that although immunochromatographic assay rapid tests may be a fast and profitable screening tool for SARS-CoV-2 infection, they may have a high false positive rate and low positive predictive value in pregnant women. Therefore, immunochromatographic assay for qualitative detection of SARS-CoV-2 IgG/IgM antibodies must be verified by other test in pregnant patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Clinical phenotypes for risk stratification in small-for-gestational-age fetuses

  • Ruiz-Martinez, S.
  • Delgado, J. L.
  • Paules, C.
  • Cavallaro, A.
  • De Paco, C.
  • Villar, J.
  • Papageorghiou, A.
  • Oros, D.
ABSTRACTObjectiveTo evaluate whether clinical phenotypes of small‐for‐gestational‐age (SGA) fetuses can be identified and used for adverse perinatal outcome risk stratification to facilitate clinical decision‐making.MethodsThis was a multicenter observational cohort study conducted in two tertiary care university hospitals. SGA fetuses were classified according to maternal, fetal and placental conditions using a two‐step cluster algorithm, in which fetuses with more than one condition were assigned to the cluster associated with the highest mortality risk. Delivery and perinatal outcomes were compared using chi‐square test among SGA clusters, and the associations between outcomes and each cluster were evaluated by calculating odds ratios (OR), adjusted for gestational age.ResultsThe study included 17 631 consecutive singleton pregnancies, of which 1274 (7.2%) were defined as SGA at birth according to INTERGROWTH‐21st standards. Nine SGA clinical phenotypes were identified using a predefined conceptual framework. All delivery and perinatal outcomes analyzed were significantly different among the nine phenotypes. The whole SGA cohort had a three‐times higher risk of perinatal mortality compared with non‐SGA fetuses (1.4% vs 0.4%; P < 0.001). SGA clinical phenotypes exhibited three patterns of perinatal mortality risk: the highest risk was associated with congenital anomaly (8.3%; OR, 17.17 (95% CI, 2.17–136.12)) and second‐ or third‐trimester hemorrhage (8.3%; OR, 9.94 (95% CI, 1.23–80.02)) clusters; medium risk was associated with gestational diabetes (3.8%; OR, 9.59 (95% CI, 1.27–72.57)), preterm birth (3.2%; OR, 4.65 (95% CI, 0.62–35.01)) and intrauterine growth restriction (3.1%; OR, 5.93 (95% CI, 3.21–10.95)) clusters; and the lowest risk was associated with the remaining clusters. Perinatal mortality rate did not differ between SGA fetuses without other clinical conditions (54.1% of SGA fetuses) and appropriate‐for‐gestational‐age fetuses (0.1% vs 0.4%; OR, 0.41 (95% CI, 0.06–2.94); P = 0.27). SGA combined with other obstetric pathologies increased significantly the risk of perinatal mortality, as demonstrated by the increased odds of perinatal death in SGA cases with gestational diabetes compared to non‐SGA cases with the same condition (OR, 24.40 (95% CI, 1.31–453.91)).ConclusionsWe identified nine SGA clinical phenotypes associated with different patterns of risk for adverse perinatal outcome. Our findings suggest that considering clinical characteristics in addition to ultrasound findings could improve risk stratification and decision‐making for management of SGA fetuses. Future clinical trials investigating management of fetuses with SGA should take into account clinical information in addition to Doppler parameters and estimated fetal weight. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.